Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Orexo News

    1,386 € +0,29% +0,004 €
    09:15:39 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0HG6G
    ISIN: SE0000736415
    US-Symbol: ORXOF
    Typ: Aktie

    Orexo News

    24.07.23 - PR Newswire
    Orexo's patent win for ZUBSOLV® appealed
    Orexo's patent win for ZUBSOLV® appealed PR Newswire
    24.07.23 - PR Newswire
    Orexo's patent win for ZUBSOLV® appealed
    Orexo's patent win for ZUBSOLV® appealed PR Newswire
    14.07.22 - PLX
    Orexo Q2 EBIT SEK -49.7 Million
    (PLX AI) – Orexo Q2 revenue SEK 147.8 million. • Q2 EBITDA SEK -32.5 million • Q2 EPS SEK -1.04
    28.04.22 - PLX
    Orexo Q1 EBIT SEK -13.2 Million
    (PLX AI) – Orexo Q1 revenue SEK 159.4 million. • Q1 EBITDA SEK 2.8 million • Q1 EPS SEK -0.69
    27.01.22 - PLX
    Orexo Q4 EBIT SEK -64.1 Million vs. Estimate SEK -51 Million
    (PLX AI) – Orexo Q4 revenue SEK 144 million vs. estimate SEK 140 million. • Q4 EBITDA SEK -48.5 million vs. estimate SEK -40 million • Q4 EPS SEK -1.92
    16.11.21 - PLX
    Orexo to File for OX124 FDA Approval; Sees U.S. Launch in H2 2023
    (PLX AI) – Orexo pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers. • OX124 showed a significantly ...
    03.11.21 - PLX
    Orexo Q3 EBIT SEK -59 Million
    (PLX AI) – Orexo Q3 revenue SEK 145.9 million. • Q3 EBITDA SEK -47.4 million • Q3 EPS SEK -1.51
    16.07.21 - PR Newswire
    Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
    Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the ...
    16.07.21 - PR Newswire
    Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
    Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the ...
    15.07.21 - PR Newswire
    Orexo Q2 2021 Interim Report
    Orexo Q2 2021 Interim Report PR Newswire
    15.07.21 - PR Newswire
    Orexo Q2 2021 Interim Report
    Orexo Q2 2021 Interim Report PR Newswire
    15.07.21 - PLX
    Orexo Q2 EBIT SEK -54 Million vs. Estimate SEK -45 Million
    (PLX AI) – Orexo Q2 revenue SEK 142.8 million vs. estimate SEK 151 million. • Q2 EBITDA SEK -41.1 million vs. estimate SEK -38 million • Q2 EPS SEK -2.15
    12.07.21 - PR Newswire
    Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
    Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis® With more than ...
    01.07.21 - PR Newswire
    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital ...
    01.07.21 - PR Newswire
    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital ...
    02.06.21 - PR Newswire
    Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents
    Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents PR Newswire
    29.04.21 - PR Newswire
    Orexo Q1 2021 Interim Report
    Orexo Q1 2021 Interim Report PR Newswire
    29.04.21 - PR Newswire
    Orexo Q1 2021 Interim Report
    Orexo Q1 2021 Interim Report Investing in future growth drivers PR Newswire
    23.03.21 - PR Newswire
    Orexo publishes Annual Report for 2020
    Orexo publishes Annual Report for 2020 PR Newswire
    10.02.21 - PR Newswire
    Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
    Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management PR Newswire

    Newssuche

    Videos

    newspaper
    08:40 Uhr +9,05%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »